Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,088 across all filing types
Latest filing 2023-07-31 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
董事会决议公告
Regulatory Filings Classification · 95% confidence The document is an announcement of the board of directors meeting resolution where the 2023 semi-annual report and its summary were approved. It states that the full report and summary are available on the official disclosure website, indicating this document itself is not the full interim report but an announcement of its approval. The document length is short (672 characters), and it mainly serves to inform about the board resolution rather than provide substantive financial data or analysis. Therefore, it fits best as a Regulatory Filing (RNS) rather than the actual Interim/Quarterly Report (IR).
2023-07-31 Chinese
2023年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "厦门艾德生物医药科技股份有限公司 2023 年半年度报告全文" which translates to "Amoy Diagnostics Co., Ltd. 2023 Semi-Annual Report Full Text." It explicitly states it is a half-year report covering the period from January 1, 2023 to June 30, 2023. The content includes detailed financial data, management discussion and analysis, company overview, business segments, and other comprehensive information typical of an interim or quarterly report. The document length is substantial (15,000 characters), and it contains actual financial statements and substantive analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2023-07-31 Chinese
关于公司非经营性资金占用及其他关联资金往来情况的专项报告
Interim / Quarterly Report Classification · 90% confidence The document is a specialized report detailing the company's non-operating fund occupation and other related party fund transactions for the half-year period of 2023. It contains detailed financial data such as balances, amounts, and accounting subjects related to these transactions. The document is not a full interim or annual financial report but a specific financial disclosure related to related party transactions and fund usage. It is not an announcement or a certification but a substantive financial report. Given the nature of the content and the focus on a specific financial aspect for a half-year period, this fits best under the category of Interim / Quarterly Report (IR), which covers comprehensive financial reports for periods shorter than a full fiscal year and includes substantive financial data and analysis.
2023-07-31 Chinese
2023年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "2023 年半年度报告摘要" which translates to "2023 Semi-Annual Report Summary". It contains detailed financial data such as revenue, net profit, earnings per share, total assets, and shareholder information for the half-year period. The presence of substantive financial data and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is 2637 characters, which is typical for a summary but still contains actual financial figures, so it is not merely an announcement or a certification. Therefore, the correct classification is Interim / Quarterly Report (IR).
2023-07-31 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolution passed at the 11th meeting of the 3rd Supervisory Board of Xiamen Aide Biomedical Technology Co., Ltd. It specifically states that the Supervisory Board has reviewed and approved the company's 2023 semi-annual report and its summary. The document confirms the legality and accuracy of the report but does not contain the actual financial data or the report itself. It also directs readers to the official disclosure website for the full report. The document length is short (676 characters) and serves as a notice of the approval of the interim report rather than the report itself. According to the classification rules, this type of document is best classified as a Regulatory Filing (RNS) because it is an announcement related to a report but does not contain the substantive financial data or analysis required for an Interim/Quarterly Report (IR).
2023-07-31 Chinese
关于与阿斯利康达成靶向药物伴随诊断合作的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Xiamen Aide Biological Pharmaceutical Technology Co., Ltd. about a cooperation agreement with AstraZeneca regarding targeted drug companion diagnostics. It details the nature of the collaboration, the parties involved, and the expected impact on the company. The document is short (1319 characters) and does not contain any financial statements, regulatory certifications, or detailed financial data. It is an announcement of a business cooperation agreement rather than a financial report or regulatory filing. Therefore, it fits best under the category of a general Regulatory Filing (RNS) as it is a regulatory announcement that does not fit into more specific categories like financial reports, management changes, or capital updates.
2023-07-24 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.